Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies.
We have studied the feasibility, safety and efficacy of vaccination with autologous dendritic cells pulsed with eluted peptide in patients with advanced low-grade B-cell malignancies. This study demonstrates that autologous dendritic cell vaccines can be successfully produced from patients with advanced disease and be delivered without significant toxicity. Furthermore, we have demonstrated immunological and clinical responses in two of ten patients treated. These results provide further evidence for the use of immunotherapy in the management of B-cell malignancies, but also suggest that sustained responses may only be possible in patients with low bulk disease early in the disease course.
Ritchie
David
D
Malaghan Institute of Medical Research, Wellington, New Zealand. david.ritchie@petermac.org
Hermans
Ian
I
Yang
Jianping
J
Walton
Julie
J
Matthews
Kate
K
Carter
John
J
Findlay
Michael
M
Dady
Peter
P
Rawson
Pisana
P
Ronchese
Franca
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001402:B-Lymphocytes / Q000378:metabolism*; D019496:Cancer Vaccines / Q000737:chemistry*; D003713:Dendritic Cells / Q000166:cytology* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000737:chemistry; D014057:Tomography, X-Ray Computed / Q000379:methods
D019496:Cancer Vaccines; D010455:Peptides